Aster Capital Management DIFC Ltd Buys 22,008 Shares of Illumina, Inc. (NASDAQ:ILMN)

Aster Capital Management DIFC Ltd increased its position in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 10,683.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 22,214 shares of the life sciences company's stock after acquiring an additional 22,008 shares during the period. Illumina makes up about 1.1% of Aster Capital Management DIFC Ltd's investment portfolio, making the stock its 9th biggest position. Aster Capital Management DIFC Ltd's holdings in Illumina were worth $2,968,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Captrust Financial Advisors lifted its position in Illumina by 6.5% during the third quarter. Captrust Financial Advisors now owns 8,576 shares of the life sciences company's stock worth $1,118,000 after buying an additional 524 shares during the period. Investment Management Corp of Ontario lifted its holdings in shares of Illumina by 43.4% during the 3rd quarter. Investment Management Corp of Ontario now owns 5,290 shares of the life sciences company's stock worth $690,000 after acquiring an additional 1,600 shares during the period. Integrated Wealth Concepts LLC lifted its holdings in shares of Illumina by 4.7% during the 3rd quarter. Integrated Wealth Concepts LLC now owns 2,990 shares of the life sciences company's stock worth $390,000 after acquiring an additional 135 shares during the period. Royal London Asset Management Ltd. boosted its position in shares of Illumina by 4.1% in the third quarter. Royal London Asset Management Ltd. now owns 65,082 shares of the life sciences company's stock worth $8,487,000 after acquiring an additional 2,555 shares during the last quarter. Finally, Quantinno Capital Management LP grew its holdings in Illumina by 29.5% in the third quarter. Quantinno Capital Management LP now owns 12,644 shares of the life sciences company's stock valued at $1,649,000 after purchasing an additional 2,879 shares during the period. 89.42% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Wall Street Analyst Weigh In

Several brokerages recently weighed in on ILMN. Stephens reaffirmed an "overweight" rating and issued a $156.00 target price on shares of Illumina in a research report on Tuesday, March 11th. Citigroup dropped their price target on Illumina from $90.00 to $85.00 and set a "neutral" rating for the company in a research note on Monday. Morgan Stanley reduced their price objective on Illumina from $150.00 to $136.00 and set an "equal weight" rating on the stock in a research note on Tuesday, February 11th. Guggenheim dropped their target price on shares of Illumina from $170.00 to $150.00 and set a "buy" rating for the company in a research report on Friday, February 7th. Finally, Robert W. Baird reduced their price target on shares of Illumina from $127.00 to $90.00 and set a "neutral" rating on the stock in a research report on Wednesday, March 5th. One research analyst has rated the stock with a sell rating, ten have given a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $138.70.

Illumina Stock Performance

Illumina stock traded up $1.83 during midday trading on Friday, reaching $73.09. 1,210,935 shares of the stock traded hands, compared to its average volume of 2,253,769. Illumina, Inc. has a fifty-two week low of $68.70 and a fifty-two week high of $156.66. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63. The firm has a market cap of $11.58 billion, a price-to-earnings ratio of -9.53, a PEG ratio of 1.60 and a beta of 1.38. The firm has a fifty day moving average price of $89.57 and a two-hundred day moving average price of $122.68.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. On average, equities research analysts forecast that Illumina, Inc. will post 4.51 earnings per share for the current year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.